Chemoradiation in NSCLC

focus on the role of gemcitabine.

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Research to identify the optimal drugs for use in chemoradiotherapy has led to the development of the potent radiosensitizing agent gemcitabine (Gemzar), which has exhibited excellent activity in non-small-cell cancer. When used in sequential chemoradiotherapy regimens, gemcitabine has been associated with response rates of 57% to 68%. A full dose of gemcitabine (1,000 mg/m2) can be safely used as induction therapy, and there is no definitive indication of enhancement of radiotoxicity. In addition, results from phase I/II trials support the efficacy of concurrent gemcitabine/radiation therapy in improving overall response rates and overall survival. Rates of 68%, 37%, and 28%, respectively, for 1-, 2-, and 3-year survival have been reported for gemcitabine/cisplatin chemotherapy administered concurrently with radiotherapy. Although the optimal dose has yet to be determined, a weekly dose of 300 mg/m2 appears to be effective with an acceptable toxicity level. Additional clinical trials are warranted to assess the long-term efficacy and safety of gemcitabine in combination with other chemotherapeutic agents and radiation therapy for treatment of non-small-cell lung cancer.

Original languageEnglish (US)
Pages (from-to)38-42
Number of pages5
JournalOncology (Williston Park, N.Y.)
Volume18
Issue number8 Suppl 5
StatePublished - Jul 2004

Fingerprint

gemcitabine
Radiotherapy
Chemoradiotherapy
Radiation-Sensitizing Agents
Non-Small Cell Lung Carcinoma
Cisplatin
Clinical Trials

ASJC Scopus subject areas

  • Oncology

Cite this

Chemoradiation in NSCLC : focus on the role of gemcitabine. / Choy, Hak.

In: Oncology (Williston Park, N.Y.), Vol. 18, No. 8 Suppl 5, 07.2004, p. 38-42.

Research output: Contribution to journalArticle

@article{5d9375921d444bbc91d6d4ba4ce35a63,
title = "Chemoradiation in NSCLC: focus on the role of gemcitabine.",
abstract = "Research to identify the optimal drugs for use in chemoradiotherapy has led to the development of the potent radiosensitizing agent gemcitabine (Gemzar), which has exhibited excellent activity in non-small-cell cancer. When used in sequential chemoradiotherapy regimens, gemcitabine has been associated with response rates of 57{\%} to 68{\%}. A full dose of gemcitabine (1,000 mg/m2) can be safely used as induction therapy, and there is no definitive indication of enhancement of radiotoxicity. In addition, results from phase I/II trials support the efficacy of concurrent gemcitabine/radiation therapy in improving overall response rates and overall survival. Rates of 68{\%}, 37{\%}, and 28{\%}, respectively, for 1-, 2-, and 3-year survival have been reported for gemcitabine/cisplatin chemotherapy administered concurrently with radiotherapy. Although the optimal dose has yet to be determined, a weekly dose of 300 mg/m2 appears to be effective with an acceptable toxicity level. Additional clinical trials are warranted to assess the long-term efficacy and safety of gemcitabine in combination with other chemotherapeutic agents and radiation therapy for treatment of non-small-cell lung cancer.",
author = "Hak Choy",
year = "2004",
month = "7",
language = "English (US)",
volume = "18",
pages = "38--42",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "8 Suppl 5",

}

TY - JOUR

T1 - Chemoradiation in NSCLC

T2 - focus on the role of gemcitabine.

AU - Choy, Hak

PY - 2004/7

Y1 - 2004/7

N2 - Research to identify the optimal drugs for use in chemoradiotherapy has led to the development of the potent radiosensitizing agent gemcitabine (Gemzar), which has exhibited excellent activity in non-small-cell cancer. When used in sequential chemoradiotherapy regimens, gemcitabine has been associated with response rates of 57% to 68%. A full dose of gemcitabine (1,000 mg/m2) can be safely used as induction therapy, and there is no definitive indication of enhancement of radiotoxicity. In addition, results from phase I/II trials support the efficacy of concurrent gemcitabine/radiation therapy in improving overall response rates and overall survival. Rates of 68%, 37%, and 28%, respectively, for 1-, 2-, and 3-year survival have been reported for gemcitabine/cisplatin chemotherapy administered concurrently with radiotherapy. Although the optimal dose has yet to be determined, a weekly dose of 300 mg/m2 appears to be effective with an acceptable toxicity level. Additional clinical trials are warranted to assess the long-term efficacy and safety of gemcitabine in combination with other chemotherapeutic agents and radiation therapy for treatment of non-small-cell lung cancer.

AB - Research to identify the optimal drugs for use in chemoradiotherapy has led to the development of the potent radiosensitizing agent gemcitabine (Gemzar), which has exhibited excellent activity in non-small-cell cancer. When used in sequential chemoradiotherapy regimens, gemcitabine has been associated with response rates of 57% to 68%. A full dose of gemcitabine (1,000 mg/m2) can be safely used as induction therapy, and there is no definitive indication of enhancement of radiotoxicity. In addition, results from phase I/II trials support the efficacy of concurrent gemcitabine/radiation therapy in improving overall response rates and overall survival. Rates of 68%, 37%, and 28%, respectively, for 1-, 2-, and 3-year survival have been reported for gemcitabine/cisplatin chemotherapy administered concurrently with radiotherapy. Although the optimal dose has yet to be determined, a weekly dose of 300 mg/m2 appears to be effective with an acceptable toxicity level. Additional clinical trials are warranted to assess the long-term efficacy and safety of gemcitabine in combination with other chemotherapeutic agents and radiation therapy for treatment of non-small-cell lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=16644384419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16644384419&partnerID=8YFLogxK

M3 - Article

VL - 18

SP - 38

EP - 42

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 8 Suppl 5

ER -